Terashita Z, Takatani M, Nishikawa K
Biology Research Laboratory, Takeda Chemical Industries, Ltd, Osaka, Japan.
J Lipid Mediat. 1992 Jun-Jul;5(2):183-5.
TCV-309 potently and specifically inhibited the diverse biological actions of PAF such as platelet aggregation, hypotension, increased vascular permeability, bronchoconstriction and death. TCV-309 did not cause hemolysis or vascular irritation. TCV-309 showed beneficial effects on experimental endotoxic shock, anaphylactic shock and disseminated intravascular coagulation.
TCV - 309能有效且特异性地抑制血小板活化因子（PAF）的多种生物学活性，如血小板聚集、低血压、血管通透性增加、支气管收缩及死亡。TCV - 309不会引起溶血或血管刺激。TCV - 309对实验性内毒素休克、过敏性休克及弥散性血管内凝血显示出有益作用。
